1579P - The efficacy of triplet antiemetic therapy for chemotherapy-induced nausea and vomiting in lung cancer patients receiving highly emetogenic chemothe...
|Date||01 October 2012|
|Event||ESMO Congress 2012|
|Session||Poster presentation III|
|Topics|| Supportive Care
Lung and other Thoracic Tumours
H. Yoshizawa1, K. Sato2, M. Makino3, O. Kobayashi4, H. Tanaka5, S. Miura6, S. Watanabe1, J. Tanaka7, H. Kagamu6, N. Ichiei6
Chemotherapy-induced nausea and vomiting (CINV) is one of the most problematic symptoms experienced by patients undergoing cancer treatments. Triplet therapy with PALO, APR, and DEX, is a guideline-recommended antiemetic prophylaxis for highly emetogenic chemotherapy (HEC). However, the efficacy and safety of this therapy for lung cancer patients has not yet been well investigated.Methods
Chemotherapy naïve lung cancer patients scheduled to receive HEC were enrolled in this study. The eligible patients were pretreated with the triplet therapy (PALO 0.75 mg day 1, APR 125 mg day 1 and 80 mg day 2-3, DEX 9.9 mg day 1 and 8 mg day 2-4) before receiving HEC. The efficacy and safety of these substances were assessed during an observation period starting from the administration of HEC to 120 hours. A questionnaire diary documented patients' complaints. The primary endpoint was the proportion of the patients who did not experience emesis or rescue antiemetic (Complete Response rate; CR rate) during any part of the whole observation period. The secondary endpoints were (1) the CR rate during the acute phase (0-24hrs) and the late phase (24-120hrs), (2) the proportion of patients who experienced no emetic episodes and significant nausea with no rescue medication (Complete Control rate; CC rate), and (3) safety.Results
A total of 72 patients were enrolled with 65 assessable patients at the time of submission. The median age was 64 years. The CR rate during the whole observation period, the acute and late phase was 78.5 %, 95.4% and 80.0%, respectively. The CC rate in the late phase was 62.9%. No severe side effects were observed. In the subset analysis, the CC rate in late phase was significantly lower in female subset (71.4% vs. 45.0%). Another subset analysis regarding to chemotherapy regimen, the proportion of vomiting event was higher in the pemetrexed used regimen.Conclusion
Triplet therapy using PALO, APR and DEX, was shown to be safe and effective in preventing CINV in lung cancer patients treated with HEC. Further investigation is needed for to reduce nausea in the late phase.Disclosure
All authors have declared no conflicts of interest.